Samuel Sossalla1, Dirk Vollmann2. 1. Department of Internal Medicine II, Cardiology, Pneumology, Intensive Care, University Hospital Regensburg. 2. Herz- & Gefäßzentrum Göttingen.
Abstract
BACKGROUND: Heart failure affects 1–2% of the population and is associated with elevated morbidity and mortality. Cardiac arrhythmias are often a result of heart failure, but they can cause left-ventricular systolic dysfunction (LVSD) as an arrhythmia-induced cardiomyopathy (AIC). This causal relationship should be borne in mind by the physician treating a patient with systolic heart failure in association with cardiac arrhythmia. METHODS: This review is based on pertinent publications retrieved by a selective search in PubMed (1987–2017) and on the recommendations in current guidelines. RESULTS: The key criterion for the diagnosis of an AIC is the demonstration of a persistent arrhythmia (including pathological tachycardia) together with an LVSD whose origin cannot be explained on any other basis. Nearly any type of tachyarrhythmia or frequent ventricular extrasystoles can lead, if persistent, to a progressively severe LVSD. The underlying pathophysiologic mechanisms are incompletely understood; the increased ventricular rate, asynchronous cardiac contractions, and neurohumoral activation all seem to play a role. The most common precipitating factors are supraventricular tachycardias in children and atrial fibrillation in adults. Recent studies have shown that the causal significance of atrial fibrillation in otherwise unexplained LVSD is underappreciated. The treatment of AIC consists primarily of the treatment of the underlying arrhythmia, generally with drugs such as beta-blockers and amiodarone. Depending on the type of arrhythmia, catheter ablation for long-term treatment should also be considered where appropriate. The diagnosis of AIC is considered to be well established when the LVSD normalizes or improves within a few weeks or months of the start of targeted treatment of the arrhythmia. CONCLUSION: An AIC is potentially reversible. The timely recognition of this condition and the appropriate treatment of the underlying arrhythmia can substantially improve patient outcomes.
BACKGROUND:Heart failure affects 1–2% of the population and is associated with elevated morbidity and mortality. Cardiac arrhythmias are often a result of heart failure, but they can cause left-ventricular systolic dysfunction (LVSD) as an arrhythmia-induced cardiomyopathy (AIC). This causal relationship should be borne in mind by the physician treating a patient with systolic heart failure in association with cardiac arrhythmia. METHODS: This review is based on pertinent publications retrieved by a selective search in PubMed (1987–2017) and on the recommendations in current guidelines. RESULTS: The key criterion for the diagnosis of an AIC is the demonstration of a persistent arrhythmia (including pathological tachycardia) together with an LVSD whose origin cannot be explained on any other basis. Nearly any type of tachyarrhythmia or frequent ventricular extrasystoles can lead, if persistent, to a progressively severe LVSD. The underlying pathophysiologic mechanisms are incompletely understood; the increased ventricular rate, asynchronous cardiac contractions, and neurohumoral activation all seem to play a role. The most common precipitating factors are supraventricular tachycardias in children and atrial fibrillation in adults. Recent studies have shown that the causal significance of atrial fibrillation in otherwise unexplained LVSD is underappreciated. The treatment of AIC consists primarily of the treatment of the underlying arrhythmia, generally with drugs such as beta-blockers and amiodarone. Depending on the type of arrhythmia, catheter ablation for long-term treatment should also be considered where appropriate. The diagnosis of AIC is considered to be well established when the LVSD normalizes or improves within a few weeks or months of the start of targeted treatment of the arrhythmia. CONCLUSION: An AIC is potentially reversible. The timely recognition of this condition and the appropriate treatment of the underlying arrhythmia can substantially improve patient outcomes.
Authors: Cevher Ozcan; Arshad Jahangir; Paul A Friedman; Thomas M Munger; Douglas L Packer; David O Hodge; David L Hayes; Bernard J Gersh; Stephen C Hammill; Win-Kuang Shen Journal: Am J Cardiol Date: 2003-07-01 Impact factor: 2.778
Authors: I C Van Gelder; H J Crijns; P K Blanksma; M L Landsman; J L Posma; M P Van Den Berg; F L Meijler; K I Lie Journal: Am J Cardiol Date: 1993-09-01 Impact factor: 2.778
Authors: Jean-Francois Sarrazin; Troy Labounty; Michael Kuhne; Thomas Crawford; William F Armstrong; Benoit Desjardins; Eric Good; Krit Jongnarangsin; Aman Chugh; Hakan Oral; Frank Pelosi; Fred Morady; Frank Bogun Journal: Heart Rhythm Date: 2009-08-05 Impact factor: 6.343
Authors: Rakesh Gopinathannair; Susan P Etheridge; Francis E Marchlinski; Francis G Spinale; Dhanunjaya Lakkireddy; Brian Olshansky Journal: J Am Coll Cardiol Date: 2015-10-13 Impact factor: 24.094
Authors: Alexander Dietl; Ingrid Winkel; Gabriela Pietrzyk; Michael Paulus; Astrid Bruckmann; Josef A Schröder; Samuel Sossalla; Andreas Luchner; Lars S Maier; Christoph Birner Journal: PLoS One Date: 2019-12-04 Impact factor: 3.240
Authors: Kathrin Renner; Alexander G Nickel; Michael G Paulus; Christoph Brochhausen; Katharina Limm; Elmar Zügner; Maria J Baier; Steffen Pabel; Stefan Wallner; Christoph Birner; Andreas Luchner; Christoph Magnes; Peter J Oefner; Klaus J Stark; Stefan Wagner; Christoph Maack; Lars S Maier; Katrin Streckfuss-Bömeke; Samuel Sossalla; Alexander Dietl Journal: Basic Res Cardiol Date: 2022-09-06 Impact factor: 12.416
Authors: Jörg Eiringhaus; Okka W Hamer; David Hollemann; Christoph Brochhausen; Dirk Vollmann; Lars S Maier; Samuel Sossalla Journal: ESC Heart Fail Date: 2018-08-06
Authors: Samantha L Fousse; William D Tyrrell; Mariellen E Dentino; Frances L Abrams; Steven L Rosenthal; Joshua A Stern Journal: Canine Genet Epidemiol Date: 2019-12-09